Socioeconomic Impact of Recurrent Primary Spontaneous Pneumothorax: Should Video-Assisted Thoracoscopic Surgery Be Considered at First Episode of Primary Spontaneous Pneumothorax?
primary spontaneous pneumothorax
recurrence
socioeconomic impact
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
19 Sep 2021
19 Sep 2021
Historique:
received:
17
08
2021
revised:
13
09
2021
accepted:
16
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Current guidelines recommend video-assisted thoracoscopic surgery (VATS) for recurrent primary spontaneous pneumothorax (PSP) and for cases with persistent air leak after chest tube treatment. The socioeconomic impact of recurrent PSP on the healthcare system is insufficiently reported. Ninety-six patients treated for PSP between 01/2010 and 01/2020 were included. Forty-eight patients underwent primary VATS, while the second group received chest tube (CT) treatment only. Length of hospital stay (LOS), duration of chest tube, prolonged air leak, postoperative complications, recurrences and treatment costs were analyzed. Prolonged air leaks were evident in 12.5% and 22.9% patients of the VATS and CT group, respectively. Ten (20.8%) patients in the CT group underwent VATS for persistent air leakage. During follow-up, the VATS group recurred at 8.3% compared to 52.1% in the CT group. The total cost of treatment per patient, including treatment cost due to recurrence, was EUR 1.501 in the VATS group and EUR 2.233 in the CT group. Primary treatment of PSP by CT is associated with an increased socioeconomic burden for patients and the healthcare system due to high recurrence rates. This burden may be reduced if VATS is considered at the first episode of PSP.
Sections du résumé
BACKGROUND
BACKGROUND
Current guidelines recommend video-assisted thoracoscopic surgery (VATS) for recurrent primary spontaneous pneumothorax (PSP) and for cases with persistent air leak after chest tube treatment. The socioeconomic impact of recurrent PSP on the healthcare system is insufficiently reported.
METHODS
METHODS
Ninety-six patients treated for PSP between 01/2010 and 01/2020 were included. Forty-eight patients underwent primary VATS, while the second group received chest tube (CT) treatment only. Length of hospital stay (LOS), duration of chest tube, prolonged air leak, postoperative complications, recurrences and treatment costs were analyzed.
RESULTS
RESULTS
Prolonged air leaks were evident in 12.5% and 22.9% patients of the VATS and CT group, respectively. Ten (20.8%) patients in the CT group underwent VATS for persistent air leakage. During follow-up, the VATS group recurred at 8.3% compared to 52.1% in the CT group. The total cost of treatment per patient, including treatment cost due to recurrence, was EUR 1.501 in the VATS group and EUR 2.233 in the CT group.
CONCLUSIONS
CONCLUSIONS
Primary treatment of PSP by CT is associated with an increased socioeconomic burden for patients and the healthcare system due to high recurrence rates. This burden may be reduced if VATS is considered at the first episode of PSP.
Identifiants
pubmed: 34575010
pii: healthcare9091236
doi: 10.3390/healthcare9091236
pmc: PMC8466303
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Cardiothorac Surg. 2018 Jul 1;54(1):113-121
pubmed: 29509892
Am J Surg. 2015 Jul;210(1):68-73
pubmed: 25769881
Am J Respir Crit Care Med. 2002 May 1;165(9):1240-4
pubmed: 11991872
N Engl J Med. 2000 Mar 23;342(12):868-74
pubmed: 10727592
Eur Respir J. 2006 Mar;27(3):477-82
pubmed: 16507846
Eur J Cardiothorac Surg. 2001 Jul;20(1):42-5
pubmed: 11423272
Eur J Cardiothorac Surg. 2019 Nov 1;56(5):819-829
pubmed: 31329896
World J Surg. 2016 Sep;40(9):2163-70
pubmed: 27091206
Chest. 2001 Feb;119(2):590-602
pubmed: 11171742
Curr Opin Pulm Med. 2003 Jul;9(4):272-5
pubmed: 12806239
Saudi J Med Med Sci. 2018 May-Aug;6(2):100-103
pubmed: 30787829
Respiration. 2019;97(4):370-402
pubmed: 30041191
Thorax. 2010 Aug;65 Suppl 2:ii18-31
pubmed: 20696690
Eur Respir J. 1996 Sep;9(9):1821-5
pubmed: 8880097
Eur J Cardiothorac Surg. 1996;10(7):556-60
pubmed: 8855429
Eur J Cardiothorac Surg. 2016 Mar;49(3):854-9
pubmed: 26094014
Eur Respir J. 2015 Aug;46(2):321-35
pubmed: 26113675
Chest. 2005 Jun;127(6):2226-30
pubmed: 15947341
Psychiatry Investig. 2017 Nov;14(6):795-800
pubmed: 29209383